ERBB2 and cancer: Unlike the cancer subtypes involving the hormone receptor or HER2 markers that govern the choice of target therapy, the main aim of systemic treatment is to disrupt cancer cell survival in the TNBC subtype through chemotherapy regimens involving anthracyclines, alkylates, taxanes, and/or platinum [13,14,15].